Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enantiospecific Pharmacogenomics of Fluvastatin

16 Apr 2019

Abstract excerpt

The aim of this study was to investigate how variability in multiple genes related to pharmacokinetics affects fluvastatin exposure. We determined fluvastatin enantiomer pharmacokinetics and sequenced 379 pharmacokinetic genes in 200 healthy volunteers. CYP2C9*3 associated with significantly increased area under the plasma concentration‐time curve (AUC) of both 3R,5S‐fluvastatin and 3S,5R‐fluvastatin (by 67% and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lipoproteins and Cardiovascular Health
Share to Peroxisome Proliferator-Activated Receptors
Share to Pharmacogenetics and Drug Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30989645
DOI: 10.1002/cpt.1463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enantiospecific Pharmacogenomics of FluvastatinPMID 30989645Read ↗

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.Semantic proximity Read ↗

Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis.Semantic proximity Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

The pharmacogenomics of statins.Semantic proximity Read ↗

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.Semantic proximity Read ↗

Genomewide Association Study of Simvastatin Pharmacokinetics.Semantic proximity Read ↗

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.Semantic proximity Read ↗

Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka.Semantic proximity Read ↗

Comparative Analysis of Atorvastatin and Rosuvastatin Side Events and Risk Factors in the UAE Multiethnic Population: Focus on Pharmacogenomic VariantsSemantic proximity Read ↗

Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.Semantic proximity Read ↗

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.Semantic proximity Read ↗

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.